DUBLIN--(BUSINESS WIRE)--Aug 30, 2018--The "CAR-T Therapies Market, 2018-2030" report has been added to ResearchAndMarkets.com's offering.

The "CAR-T Therapies Market, 2018-2030" report features an extensive study of the current market landscape and the future potential of CAR-T therapies. One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing development programs of both small and big pharmaceutical firms.

Amidst the current initiatives to develop more targeted anti-cancer therapies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a potent and viable therapeutic intervention to eradicate tumor cells, with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. There are certain key characteristics that render CAR-T cells suitable for use as effective therapeutic tools; these include target specificity, adaptability and the capability to retain immunologic memory.

Close to 70 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential product candidates. These efforts have built the intellectual framework for the establishment of several start-ups. The ongoing innovation has also led to the discovery of several novel molecular targets, strengthening the research pipelines of various companies engaged in this domain. Given the recent approval of two CAR-T therapies, namely Kymriah (Novartis) and Yescarta (Gilead Sciences), and a robust development pipeline, the CAR-T therapy market also offers considerable promise to a number of industry stakeholders.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Chimeric Antigen Receptor-T Cell Therapy

5. Emerging Trends On Social Media

6. Market Landscape

7. Key Insights

8. Marketed And Late-Stage Car-T Therapy Profiles

9. Key Therapeutic Areas Car-T Therapies

10. Emerging Technologies

11. Case Study: Cell Therapy Manufacturing

12. T-Cell Immunotherapy: Cost Price Analysis

13. Market Sizing And Opportunity Analysis

14. Promotional Analysis

15. Company Profiles

16. Conclusion

17. Executive Insights

18. Appendix 1: Tabulated Data

19. Appendix 2: List Of Companies And Organizations

Company Profiles

Autolus bluebird bio CARsgen Therapeutics Celgene Cell Medica Cellectis Cellular Biomedicine Group Innovative Cellular Therapeutics Kite Pharma (A Gilead Sciences Company) Novartis Sinobioway Cell Therapy Takara Bio ZIOPHARM Oncology

For more information about this report visit https://www.researchandmarkets.com/research/gqwbz7/cart_therapies?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180830005324/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/30/2018 05:44 AM/DISC: 08/30/2018 05:43 AM

http://www.businesswire.com/news/home/20180830005324/en